Krystal K. Haase
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Krystal K. Haase has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Alberto Alvarez
Jerry H. Hodge School of Pharmacy and Center of Excellence in Real-World Evidence, Texas Tech University Health Sciences Center, Dallas, USA
2 shared publications - Christopher Giuliano
Wayne State University
2 shared publications - Christopher Raymond Frei
University of Texas at Austin
2 shared publications - Kathleen A Hazlewood
Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, USA
2 shared publications - Nicolas A Forcade
Division of Pharmacotherapy, University of Texas, Austin, USA
2 shared publications - Roger Bedimo
Division of Infectious Diseases, University of Texas Southwestern Medical Center , Dallas, Texas
2 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (11) , e70318
Distribution and Accessibility of Board‐Certified Pharmacists: A Cross‐Sectional Geospatial Study
Background: Health care access remains a challenge across the United States, particularly in rural areas. Board‐certified pharmacists (BCPs) have the knowledge and skills to provide high‐quality direct patient care and are a potential resource to improve health access and outcomes. However, their distribution within rural and underserved areas has not been systematically evaluated. This study aimed to characterize the geographic distribution, composition, and accessibility of the BCP workforce within the United States. Methods: A cross‐sectional geospatial study of BCPs was conducted using the 2026 Board of Pharmacy Specialties public database. BCP locations were classified using 2020 Rural–Urban Commuting Area (RUCA) codes, assigned to counties using federal crosswalk files with US Census Bureau county code validation, and examined in relation to designated health professional shortage areas (HPSAs). Analysis was performed at the postal code, county, and state levels. Provider density was calculated using 2025 census estimates, and the distribution of certification types was analyzed across geographic categories. Results: Data for 47 134 BCPs were extracted, representing 52 941 certifications. Of those, 94% were in metropolitan, 3.8% micropolitan, and 2.3% small‐town/rural areas. BCPs were absent in 44% of counties. In counties with BCPs, the median county resident‐to‐BCP ratio was 12 354:1, and BCP density ranged from 0.3 to 123.1 per 100 000 (coefficient of variation [CV] 101% vs. state‐level CV of 29%). The proportions of BCPs in geographic HPSAs were 3% and 18.9% based on postal code and aggregated county designations, respectively, with 59% of HPSA counties having none. Across RUCA categories, representation of certifications applicable to broader practice settings increased as area size decreased. Conclusion: BCPs are concentrated in metropolitan areas, limiting access to specialized medication management services for patients in small‐town and rural areas. Development of workforce benchmarks and targeted strategies to increase BCP representation in underserved areas is warranted.
- 5 November 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (11) , e70318
Open AccessDistribution and Accessibility of Board‐Certified Pharmacists: A Cross‐Sectional Geospatial Study
Background: Health care access remains a challenge across the United States, particularly in rural areas. Board‐certified pharmacists (BCPs) have the knowledge and skills to provide high‐quality direct patient care and are a potential resource to improve health access and outcomes. However, their distribution within rural and underserved areas has not been systematically evaluated. This study aimed to characterize the geographic distribution, composition, and accessibility of the BCP workforce within the United States. Methods: A cross‐sectional geospatial study of BCPs was conducted using the 2026 Board of Pharmacy Specialties public database. BCP locations were classified using 2020 Rural–Urban Commuting Area (RUCA) codes, assigned to counties using federal crosswalk files with US Census Bureau county code validation, and examined in relation to designated health professional shortage areas (HPSAs). Analysis was performed at the postal code, county, and state levels. Provider density was calculated using 2025 census estimates, and the distribution of certification types was analyzed across geographic categories. Results: Data for 47 134 BCPs were extracted, representing 52 941 certifications. Of those, 94% were in metropolitan, 3.8% micropolitan, and 2.3% small‐town/rural areas. BCPs were absent in 44% of counties. In counties with BCPs, the median county resident‐to‐BCP ratio was 12 354:1, and BCP density ranged from 0.3 to 123.1 per 100 000 (coefficient of variation [CV] 101% vs. state‐level CV of 29%). The proportions of BCPs in geographic HPSAs were 3% and 18.9% based on postal code and aggregated county designations, respectively, with 59% of HPSA counties having none. Across RUCA categories, representation of certifications applicable to broader practice settings increased as area size decreased. Conclusion: BCPs are concentrated in metropolitan areas, limiting access to specialized medication management services for patients in small‐town and rural areas. Development of workforce benchmarks and targeted strategies to increase BCP representation in underserved areas is warranted.
- 18 March 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (6) , 738-742
Clinicians' experiences and reflections from a health system cyberattack
Universal Health Services experienced a cyberattack in September 2020 that impacted all hospitals in their system. Nearly all computer systems that store and communicate patient care information were shut down to prevent malware propagation. The impact of this attack was magnified by the ongoing coronavirus disease 2019 (COVID‐19) pandemic. The objective of this paper is to describe the response of our intensive care unit (ICU) rounding team to the loss of all electronic health record (EHR) systems within our institution and to share lessons learned through the experience. Guidance is available on prevention of cyberattacks but does not effectively address the need to establish and train providers for alternative care mechanisms at the local level. Many providers and trainees have limited or no experience with manual patient care systems and had difficulty in transitioning to paper records, notes, and order writing. The transition also highlighted a number of unintended consequences that have occurred secondary to implementation and adaptation of EHRs over time. Institutional memory played a major role in addressing the crisis as providers who had utilized paper charting systems were more adaptive. Critical care pharmacists practicing as members of an integrated ICU health care team were an essential resource during the crisis, maintaining patient safety, assisting with order writing, troubleshooting medication issues, and providing education. The cyberattack provided an opportunity to re‐evaluate processes and procedures that have developed over time through the use of EHRs. The crisis magnified the importance of team‐based care and the integral role of the acute care clinical pharmacist.
- 18 March 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (6) , 738-742
Clinicians' experiences and reflections from a health system cyberattack
Universal Health Services experienced a cyberattack in September 2020 that impacted all hospitals in their system. Nearly all computer systems that store and communicate patient care information were shut down to prevent malware propagation. The impact of this attack was magnified by the ongoing coronavirus disease 2019 (COVID‐19) pandemic. The objective of this paper is to describe the response of our intensive care unit (ICU) rounding team to the loss of all electronic health record (EHR) systems within our institution and to share lessons learned through the experience. Guidance is available on prevention of cyberattacks but does not effectively address the need to establish and train providers for alternative care mechanisms at the local level. Many providers and trainees have limited or no experience with manual patient care systems and had difficulty in transitioning to paper records, notes, and order writing. The transition also highlighted a number of unintended consequences that have occurred secondary to implementation and adaptation of EHRs over time. Institutional memory played a major role in addressing the crisis as providers who had utilized paper charting systems were more adaptive. Critical care pharmacists practicing as members of an integrated ICU health care team were an essential resource during the crisis, maintaining patient safety, assisting with order writing, troubleshooting medication issues, and providing education. The cyberattack provided an opportunity to re‐evaluate processes and procedures that have developed over time through the use of EHRs. The crisis magnified the importance of team‐based care and the integral role of the acute care clinical pharmacist.
- 18 September 2020
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 3 (6) , 1157
The Author's Respond to Comment on Haase et al. Addressing burnout in clinical pharmacy: What can we learn from other health care disciplines?
- 18 September 2020
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 3 (6) , 1157
The Author's Respond to Comment on Haase et al. Addressing burnout in clinical pharmacy: What can we learn from other health care disciplines?
- 31 March 2020
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 3 (3) , 696-712
Pharmacy practice faculty and preceptor development
Faculty development is a priority for colleges and schools of pharmacy for both corporate and individual success. Recommendations in the 2008 American College of Clinical Pharmacy (ACCP) position statement and white paper on faculty development remain relevant today. However, changes in educational standards, delivery of pharmacy education, and faculty and learners have prompted an update of the 2008 documents. This 2020 white paper focuses on three components: preceptor development, updates in pharmacy practice faculty development, and program formation and implementation. The paper provides evidence and recommendations for preceptor development and summarizes the literature updates related to pharmacy practice faculty development in several areas, including teaching, practice, and research. This update explores additional topics not emphasized in the previous paper, including faculty well‐being, holistic career‐long development, and challenges with implementing and assessing development programs.
- 31 March 2020
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 3 (3) , 696-712
Pharmacy practice faculty and preceptor development
Faculty development is a priority for colleges and schools of pharmacy for both corporate and individual success. Recommendations in the 2008 American College of Clinical Pharmacy (ACCP) position statement and white paper on faculty development remain relevant today. However, changes in educational standards, delivery of pharmacy education, and faculty and learners have prompted an update of the 2008 documents. This 2020 white paper focuses on three components: preceptor development, updates in pharmacy practice faculty development, and program formation and implementation. The paper provides evidence and recommendations for preceptor development and summarizes the literature updates related to pharmacy practice faculty development in several areas, including teaching, practice, and research. This update explores additional topics not emphasized in the previous paper, including faculty well‐being, holistic career‐long development, and challenges with implementing and assessing development programs.
- Open Access
- 4 November 2019
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 3 (3) , 645-654
Addressing burnout in clinical pharmacy: What can we learn from other health care disciplines?
Burnout is a growing concern across health care disciplines. Burnout is a prolonged response to persistent work‐related stressors and includes elements of exhaustion, depersonalization, and perceived ineffectiveness. The body of literature exploring the causes and consequences of burnout has grown substantially. Rates of burnout in clinical pharmacists are similar to those reported for other health care professionals. However, many aspects of burnout have not been adequately characterized in clinical pharmacists. This manuscript outlines key findings from the literature on burnout in other health care disciplines and establishes relevant connections to clinical pharmacy. Burnout has negative consequences related to personal well‐being and is linked to stress‐related health outcomes. Burnout is associated with increased job turnover, decreased productivity, and quality concerns, including both patient safety and satisfaction. A variety of factors contribute to the development of burnout, including provider characteristics, practice specialization, type and quantity of work expectations, work environment, social and organizational support, and reward. Interventions that focus on individual providers have been shown to modestly improve burnout. Interventions that emphasize organizational change may have a more significant impact, and several groups have outlined organization‐focused strategies to improve well‐being in the workplace. Such strategies include enhancing communication, promoting true collaboration and community, addressing staffing shortages, empowering employee decision‐making, and developing and promoting institutional values. Best practices for improving well‐being within an organization include a multidisciplinary, multimodal approach that is supported by both resources and leadership engagement.
- 4 November 2019
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 3 (3) , 645-654
Open AccessAddressing burnout in clinical pharmacy: What can we learn from other health care disciplines?
Burnout is a growing concern across health care disciplines. Burnout is a prolonged response to persistent work‐related stressors and includes elements of exhaustion, depersonalization, and perceived ineffectiveness. The body of literature exploring the causes and consequences of burnout has grown substantially. Rates of burnout in clinical pharmacists are similar to those reported for other health care professionals. However, many aspects of burnout have not been adequately characterized in clinical pharmacists. This manuscript outlines key findings from the literature on burnout in other health care disciplines and establishes relevant connections to clinical pharmacy. Burnout has negative consequences related to personal well‐being and is linked to stress‐related health outcomes. Burnout is associated with increased job turnover, decreased productivity, and quality concerns, including both patient safety and satisfaction. A variety of factors contribute to the development of burnout, including provider characteristics, practice specialization, type and quantity of work expectations, work environment, social and organizational support, and reward. Interventions that focus on individual providers have been shown to modestly improve burnout. Interventions that emphasize organizational change may have a more significant impact, and several groups have outlined organization‐focused strategies to improve well‐being in the workplace. Such strategies include enhancing communication, promoting true collaboration and community, addressing staffing shortages, empowering employee decision‐making, and developing and promoting institutional values. Best practices for improving well‐being within an organization include a multidisciplinary, multimodal approach that is supported by both resources and leadership engagement.
- Open Access
- 18 September 2017
- Published by Wiley in Critical Care Research and Practice
- Vol. 2017, 1-7
Variability in Glycemic Control with Temperature Transitions during Therapeutic Hypothermia
Purpose. Patients treated with therapeutic hypothermia (TH) and continuous insulin may be at increased risk of hyperglycemia or hypoglycemia, particularly during temperature transitions. This study aimed to evaluate frequency of glucose excursions during each phase of TH and to characterize glycemic control patterns in relation to survival.Methods. Patients admitted to a tertiary care hospital for circulatory arrest and treated with both therapeutic hypothermia and protocol-based continuous insulin between January 2010 and June 2013 were included. Glucose measures, insulin, and temperatures were collected through 24 hours after rewarming.Results. 24 of 26 patients experienced glycemic excursions. Hyperglycemic excursions were more frequent during initiation versus remaining phases (36.3%, 4.3%, 2.5%, and 4.0%,). Hypoglycemia occurred most often during rewarming (0%, 7.7%, 23.1%, and 3.8%,). Patients who experienced hypoglycemia had higher insulin doses prior to rewarming (16.2 versus 2.1 units/hr,). Glucose variation was highest during hypothermia and trended higher in nonsurvivors compared to survivors (13.38 versus 9.16,). Frequency of excursions was also higher in nonsurvivors (32.3% versus 19.8%,).Conclusions. Glycemic excursions are common and occur more often in nonsurvivors. Excursions differ by phase but risk of hypoglycemia is increased during rewarming.- 18 September 2017
- Published by Wiley in Critical Care Research and Practice
- Vol. 2017, 1-7
Open AccessVariability in Glycemic Control with Temperature Transitions during Therapeutic Hypothermia
Purpose. Patients treated with therapeutic hypothermia (TH) and continuous insulin may be at increased risk of hyperglycemia or hypoglycemia, particularly during temperature transitions. This study aimed to evaluate frequency of glucose excursions during each phase of TH and to characterize glycemic control patterns in relation to survival.Methods. Patients admitted to a tertiary care hospital for circulatory arrest and treated with both therapeutic hypothermia and protocol-based continuous insulin between January 2010 and June 2013 were included. Glucose measures, insulin, and temperatures were collected through 24 hours after rewarming.Results. 24 of 26 patients experienced glycemic excursions. Hyperglycemic excursions were more frequent during initiation versus remaining phases (36.3%, 4.3%, 2.5%, and 4.0%,). Hypoglycemia occurred most often during rewarming (0%, 7.7%, 23.1%, and 3.8%,). Patients who experienced hypoglycemia had higher insulin doses prior to rewarming (16.2 versus 2.1 units/hr,). Glucose variation was highest during hypothermia and trended higher in nonsurvivors compared to survivors (13.38 versus 9.16,). Frequency of excursions was also higher in nonsurvivors (32.3% versus 19.8%,).Conclusions. Glycemic excursions are common and occur more often in nonsurvivors. Excursions differ by phase but risk of hypoglycemia is increased during rewarming. - 21 July 2017
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 37 (10) , 1231-1240
Effect of Abrupt Discontinuation of Antidepressants in Critically Ill Hospitalized Adults
Objectives: To determine whether discontinuation of chronic antidepressant therapy is associated with a higher risk of antidepressant discontinuation syndrome (ADS) symptoms in patients admitted to the intensive care unit (ICU) when compared with those who were continued on therapy and to identify factors associated with increased risk of ADS in this population.Design: Single‐center retrospective observational cohort study.Setting: ICUs in a tertiary care hospital.Patients: A total of 106 adult patients, admitted to the ICU between September 2013 and August 2014, who had a length of stay of 72 hours or longer and who were receiving chronic selective serotonin inhibitors (SSRIs) or serotonin‐norepinephrine reuptake inhibitors (SNRIs) before admission.Measurements and Main Results: Patients were classified as continued or discontinued from therapy based on initiation of home SSRI/SNRI therapy within 48 hours of admission. The primary end point was incidence of ADS symptoms. Type of symptoms, receipt of symptom‐related therapies, and length of stay were also assessed. Sequential logistic regression analysis was used to determine the impact of discontinuation while controlling for other risk factors. Therapy was discontinued in 38.7% of patients. The risk of developing ADS symptoms was higher in discontinued patients (unadjusted odds ratio [OR] 2.6, 95% confidence interval [CI] 1.12–6.07, p=0.024). After adjusting for covariates, the odds of ADS increased (adjusted OR 3.8, 95% CI 1.3–11.7, p=0.018). Female sex was associated with an increase in risk of ADS (OR 3.4, 95% CI 1.2–10.0, p=0.026). Affective symptoms were the most prevalent type reported (34.1% vs 10.8%, p=0.005). Use of symptom‐related therapies and length of stay did not differ between groups.Conclusion: Abrupt discontinuation of SSRI/SNRI therapy increases the risk of ADS symptoms in critically ill patients, particularly in females. These results underscore the importance of continuation of home antidepressant therapy even in the setting of critical illness.
- 21 July 2017
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 37 (10) , 1231-1240
Effect of Abrupt Discontinuation of Antidepressants in Critically Ill Hospitalized Adults
Objectives: To determine whether discontinuation of chronic antidepressant therapy is associated with a higher risk of antidepressant discontinuation syndrome (ADS) symptoms in patients admitted to the intensive care unit (ICU) when compared with those who were continued on therapy and to identify factors associated with increased risk of ADS in this population.Design: Single‐center retrospective observational cohort study.Setting: ICUs in a tertiary care hospital.Patients: A total of 106 adult patients, admitted to the ICU between September 2013 and August 2014, who had a length of stay of 72 hours or longer and who were receiving chronic selective serotonin inhibitors (SSRIs) or serotonin‐norepinephrine reuptake inhibitors (SNRIs) before admission.Measurements and Main Results: Patients were classified as continued or discontinued from therapy based on initiation of home SSRI/SNRI therapy within 48 hours of admission. The primary end point was incidence of ADS symptoms. Type of symptoms, receipt of symptom‐related therapies, and length of stay were also assessed. Sequential logistic regression analysis was used to determine the impact of discontinuation while controlling for other risk factors. Therapy was discontinued in 38.7% of patients. The risk of developing ADS symptoms was higher in discontinued patients (unadjusted odds ratio [OR] 2.6, 95% confidence interval [CI] 1.12–6.07, p=0.024). After adjusting for covariates, the odds of ADS increased (adjusted OR 3.8, 95% CI 1.3–11.7, p=0.018). Female sex was associated with an increase in risk of ADS (OR 3.4, 95% CI 1.2–10.0, p=0.026). Affective symptoms were the most prevalent type reported (34.1% vs 10.8%, p=0.005). Use of symptom‐related therapies and length of stay did not differ between groups.Conclusion: Abrupt discontinuation of SSRI/SNRI therapy increases the risk of ADS symptoms in critically ill patients, particularly in females. These results underscore the importance of continuation of home antidepressant therapy even in the setting of critical illness.
- Open Access
- 13 February 2013
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 14 (1) , 12
Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study
Previous studies have established a correlation between vancomycin troughs and nephrotoxicity. However, data are currently lacking regarding the effect of guideline-recommended weight-based dosing on nephrotoxicity in methicillin-resistant Staphylococcus aureus bacteremia (MRSAB).
- 13 February 2013
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 14 (1) , 12
Open AccessEmpiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study
Previous studies have established a correlation between vancomycin troughs and nephrotoxicity. However, data are currently lacking regarding the effect of guideline-recommended weight-based dosing on nephrotoxicity in methicillin-resistant Staphylococcus aureus bacteremia (MRSAB).
- Open Access
- 27 April 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 104
Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study
No studies have evaluated the effect of guideline-recommended weight-based dosing on in-hospital mortality of patients with methicillin-resistant Staphylococcus aureus bacteremia.
- 27 April 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 104
Open AccessEmpiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study
No studies have evaluated the effect of guideline-recommended weight-based dosing on in-hospital mortality of patients with methicillin-resistant Staphylococcus aureus bacteremia.
- 10 January 2010
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 8 (1) , 95-106
Use of vancomycin pharmacokinetic–pharmacodynamic properties in the treatment of MRSA infections
(2010). Use of vancomycin pharmacokinetic–pharmacodynamic properties in the treatment of MRSA infections. Expert Review of Anti-infective Therapy: Vol. 8, No. 1, pp. 95-106.
- 10 January 2010
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 8 (1) , 95-106
Use of vancomycin pharmacokinetic–pharmacodynamic properties in the treatment of MRSA infections
(2010). Use of vancomycin pharmacokinetic–pharmacodynamic properties in the treatment of MRSA infections. Expert Review of Anti-infective Therapy: Vol. 8, No. 1, pp. 95-106.